Pharma-Bio Serv Announces Full Year Results
Pharma-Bio Serv (OTCQB:PBSV) reported financial results for the fiscal year ended October 31, 2024. The company experienced a significant decline in performance, with revenues dropping to $9.5 million, representing a decrease of $7.5 million compared to the previous year. The company reported a net loss of $0.8 million, contrasting with a net income of $1.3 million in the prior year.
Despite challenging market conditions, particularly in new investments and projects, the company implemented strategic measures focusing on higher-value services and business development, including technology adoption. The Board of Directors approved a Special Dividend of $0.075 per share, payable around March 20, 2025, demonstrating confidence in their business plan and commitment to shareholder value.
Pharma-Bio Serv (OTCQB:PBSV) ha riportato i risultati finanziari per l'anno fiscale conclusosi il 31 ottobre 2024. L'azienda ha registrato un significativo calo delle performance, con i ricavi che sono scesi a 9,5 milioni di dollari, segnando una diminuzione di 7,5 milioni di dollari rispetto all'anno precedente. L'azienda ha riportato una perdita netta di 0,8 milioni di dollari, contrariamente a un utile netto di 1,3 milioni di dollari nell'anno precedente.
Nonostante le difficili condizioni di mercato, in particolare per nuovi investimenti e progetti, l'azienda ha implementato misure strategiche mirate a servizi di maggior valore e allo sviluppo commerciale, inclusa l'adozione di nuove tecnologie. Il Consiglio di Amministrazione ha approvato un Dividendo Straordinario di 0,075 dollari per azione, che sarà pagato intorno al 20 marzo 2025, dimostrando fiducia nel proprio piano aziendale e nell'impegno verso il valore per gli azionisti.
Pharma-Bio Serv (OTCQB:PBSV) informó los resultados financieros para el año fiscal que terminó el 31 de octubre de 2024. La compañía experimentó una disminución significativa en su rendimiento, con ingresos que cayeron a 9.5 millones de dólares, lo que representa una disminución de 7.5 millones de dólares en comparación con el año anterior. La empresa reportó una pérdida neta de 0.8 millones de dólares, en contraste con una ganancia neta de 1.3 millones de dólares en el año anterior.
A pesar de las desafiantes condiciones del mercado, particularmente en nuevas inversiones y proyectos, la compañía implementó medidas estratégicas centradas en servicios de mayor valor y desarrollo comercial, incluida la adopción de tecnología. La Junta Directiva aprobó un Dividendo Especial de 0.075 dólares por acción, que se pagará alrededor del 20 de marzo de 2025, demostrando confianza en su plan de negocios y compromiso con el valor para los accionistas.
Pharma-Bio Serv (OTCQB:PBSV)는 2024년 10월 31일로 종료된 회계연도에 대한 재무 결과를 보고했습니다. 이 회사는 성과의 상당한 하락을 경험했으며, 수익은 950만 달러로 감소하여 이전 해에 비해 750만 달러 줄어들었습니다. 이 회사는 80만 달러의 순손실을 기록했으며, 이는 전년도의 130만 달러의 순이익과 대조적입니다.
새로운 투자 및 프로젝트에서 특히 어려운 시장 상황에도 불구하고, 이 회사는 고부가가치 서비스와 사업 개발에 중점을 두고 전략적 조치를 시행했으며, 기술 도입도 포함되었습니다. 이사회는 주당 0.075 달러의 특별 배당금을 승인하였으며, 이는 2025년 3월 20일 경에 지급될 예정으로, 비즈니스 계획에 대한 신뢰와 주주 가치를 향한 헌신을 나타냅니다.
Pharma-Bio Serv (OTCQB:PBSV) a publié les résultats financiers pour l'exercice clos le 31 octobre 2024. L'entreprise a enregistré un déclin significatif de ses performances, avec des revenus tombant à 9,5 millions de dollars, soit une baisse de 7,5 millions de dollars par rapport à l'année précédente. La société a annoncé une perte nette de 0,8 million de dollars, contrairement à un bénéfice net de 1,3 million de dollars l'année précédente.
Malgré des conditions de marché difficiles, en particulier pour de nouveaux investissements et projets, l'entreprise a mis en place des mesures stratégiques axées sur des services de plus grande valeur et le développement commercial, y compris l'adoption de technologies. Le Conseil d'administration a approuvé un dividende spécial de 0,075 dollar par action, payable aux alentours du 20 mars 2025, témoignant de sa confiance dans son plan d'affaires et de son engagement envers la valeur pour les actionnaires.
Pharma-Bio Serv (OTCQB:PBSV) hat die finanziellen Ergebnisse für das am 31. Oktober 2024 endende Geschäftsjahr veröffentlicht. Das Unternehmen verzeichnete einen erheblichen Rückgang der Leistungen, wobei die Einnahmen auf 9,5 Millionen Dollar sanken, was einem Rückgang von 7,5 Millionen Dollar im Vergleich zum Vorjahr entspricht. Das Unternehmen meldete einen Nettoverlust von 0,8 Millionen Dollar, im Gegensatz zu einem Nettogewinn von 1,3 Millionen Dollar im Vorjahr.
Trotz herausfordernder Marktbedingungen, insbesondere bei neuen Investitionen und Projekten, hat das Unternehmen strategische Maßnahmen umgesetzt, die sich auf höherwertige Dienstleistungen und Geschäftsentwicklung konzentrieren, einschließlich der Technologieadoption. Der Vorstand genehmigte eine Sonderdividende von 0,075 Dollar pro Aktie, die etwa am 20. März 2025 ausgezahlt werden soll, was das Vertrauen in ihren Geschäftsplan und das Engagement für den Aktionärswert zeigt.
- Board approved Special Dividend of $0.075 per share payable March 20, 2025
- Strategic shift towards higher-value services and advanced technologies
- Revenue decreased by $7.5 million to $9.5 million in FY2024
- Net loss of $0.8 million in FY2024 compared to $1.3 million profit previous year
- Challenging market conditions affecting new investments and projects
DORADO, PUERTO RICO / ACCESS Newswire / January 29, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2024 were approximately
"While 2024 was a challenging year for the industries we serve, particularly in terms of new investments and projects, we took deliberate steps to address these concerns. We concentrated our efforts on higher-value services and redirected resources toward business development, including the adoption of advanced technologies. These initiatives are designed to strengthen our connections with new and existing clients and explore prospective markets in innovative ways. As we move forward, we believe these measures position us well for potential growth in 2025," stated Mr. Sanchez, Chief Executive Officer of the Company.
Mr. Sanchez continued, "Moreover, we remain financially strong and optimistic about the future of our industry. Accordingly, as announced earlier today, the Company's Board of Directors approved a Special Dividend of
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's most recent Annual Report on Form 10-K, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv, Inc.
View the original press release on ACCESS Newswire
FAQ
What was Pharma-Bio Serv's (PBSV) revenue for fiscal year 2024?
How much is PBSV's special dividend announced in January 2025?
What was Pharma-Bio Serv's net income/loss for FY 2024?
What strategic measures did PBSV implement in 2024?
